CVS Health (CVS) Stock Could Be Undervalued Following Opioid Settlement

Simply Wall St.10-21

CVS Health shares have logged a solid multi year run, and with fresh headlines ranging from an opioid settlement to changes in its health benefits business, the key issue for investors is whether the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2677179686?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/93625-card/1788942584052","is_english":true,"pubTime":"2026-10-21 07:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2677179686","market":"nz","top_or_hot":-1,"title":"CVS Health (CVS) Stock Could Be Undervalued Following Opioid Settlement","media":"Simply Wall St.","content":"<div>\n<p>CVS Health shares have logged a solid multi year run, and with fresh headlines ranging from an opioid settlement to changes in its health benefits business, the key issue for investors is whether the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/cvs-health-cvs-stock-could-be-undervalued-following-opioid-s\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVS Health (CVS) Stock Could Be Undervalued Following Opioid Settlement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVS Health (CVS) Stock Could Be Undervalued Following Opioid Settlement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-21 07:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/cvs-health-cvs-stock-could-be-undervalued-following-opioid-s><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CVS Health shares have logged a solid multi year run, and with fresh headlines ranging from an opioid settlement to changes in its health benefits business, the key issue for investors is whether the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/cvs-health-cvs-stock-could-be-undervalued-following-opioid-s\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RTH","symbol_name":"零售指数ETF-HOLDRs","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/cvs-health-cvs-stock-could-be-undervalued-following-opioid-s","article_id":"2677179686","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/93625-card/1788942584052"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/cvs-health-cvs-stock-could-be-undervalued-following-opioid-s","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2677179686","pubTimestamp":1792539504,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"CVS Health shares have logged a solid multi year run, and with fresh headlines ranging from an opioid settlement to changes in its health benefits business, the key issue for investors is whether the current price is still in line with what the company earns.\n\nOver the past 3 years the stock has returned 52.7%, which puts real weight on the question of how well its earnings support that kind of performance.\nThe US$315 million opioid settlement and related compliance commitments may affect...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"RTH":"零售指数ETF-HOLDRs","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4550":"红杉资本持仓","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","VGFPF":"Vanguard Funds PLC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","RGLO":"Global Equity Active ETF","BK4196":"保健护理服务","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0859254822.USD":"T ROWE PRICE GLOBAL VALUE EQUITY \"A\" (USD) ACC","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","LU2357627491.SGD":"TRP GLOBAL VALUE EQUITY \"AH\" (SGDHDG) ACC","BK4581":"高盛持仓","BK4585":"ETF&股票定投概念","CVS.AU":"Cervantes Corp Ltd","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","JOYT":"JPMorgan Equity and Options Total Return ETF","CVS":"西维斯健康","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","PMDE":"PGIM S&P 500 Max Buffer ETF - December","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","LU1236620750.USD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (USD) INC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4588":"碎股","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","LU1236620834.HKD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (HKD) INC","VOTE":"TCW Transform 500 ETF","IHF":"iShares Dow Jones U.S. Health Ca","GXDW":"Global X Dorsey Wright Thematic ETF","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4504":"桥水持仓"},"translate_title":"阿片类药物和解后，CVS Health (CVS) 股票可能被低估","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RTH":0.6,"PMDE":0.62,"VGFPF":0.62,"CVS.AU":1.5,"JOYT":0.62,"IHF":0.6,"VOTE":0.62,"GXDW":0.62,"RGLO":0.62,"CVS":1.5,"DECU":0.62,"FEBU":0.62},"content_text":"CVS Health shares have logged a solid multi year run, and with fresh headlines ranging from an opioid settlement to changes in its health benefits business, the key issue for investors is whether the current price is still in line with what the company earns.  Over the past 3 years the stock has returned 52.7%, which puts real weight on the question of how well its earnings support that kind of performance. The US$315 million opioid settlement and related compliance commitments may affect both legal risk and future costs, which can influence how investors assess the durability of CVS Health's profit stream. Your read on CVS Health is one view; the desks covering it have another. See what analysts think CVS Health's shares could be worth.  The issue now is whether CVS Health's current share price is adequately backed by its earnings power today and the profitability investors expect it to sustain over time. If you want to test the same earnings question you are asking of CVS Health across a wider set of companies, take a look at solid balance sheet and fundamentals stocks screener (25 results). AdvertisementIs CVS Health Still Cheap on Earnings? The P/E ratio works well for CVS Health because earnings are a central focus for how investors frame its mix of retail, insurance and pharmacy services. CVS currently trades on a P/E of 24.8x, which is close to the broader Healthcare sector average of 25.0x. Against a peer group sitting nearer 19.3x, the stock is priced at a higher multiple than many comparable insurers and pharmacy benefit players. Despite the recent opioid settlement grabbing headlines, the current P/E still leaves CVS Health at a discount to the multiple a tailored model suggests for its growth profile, margins and risk mix. That gap points to a market that is cautious on near term earnings headlines, while placing a lower valuation on the business than its longer run cash flow characteristics might imply. Explore the numbers behind CVS Health's P/E valuation. NYSE:CVS P/E Ratio as at Oct 2026 The CVS Health Narrative: What Would Justify Today's Price? Narratives pick up where the P/E debate leaves off for CVS Health by spelling out which paths for growth, profitability and earnings would need to hold for the shares to look meaningfully underpriced or overvalued at today’s level, and they sit on Simply Wall St’s Community page. Rather than relying on a single P/E or model snapshot, each scenario lays out the assumptions behind its estimate so you can compare those expectations with actual results over time. One of the top community narratives on CVS Health: 9% undervalued \"CVS Health is rebuilding itself while still operating at full scale, a difficult balancing act that has weighed on investor confidence…\" Discover why this Narrative puts CVS Health at 9% undervalued. One more angle on CVS Health that could change the story Price ratios only tell part of the story for CVS Health, because the people steering the business and how their rewards line up with your interests can tilt outcomes in important ways. See who runs CVS Health and how they are paid. This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2677179686","isCrawlerRequest":true}